MedTrace Logo

ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation

NCT01184300 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2011-11-11

No results posted yet for this study

Summary

The objective of the RAPID GENE study is to evaluate the feasibility, efficacy and safety of a pharmacogenomic approach to anti-platelet therapy following coronary artery stenting using a CYP2C19\*2 point-of-care genetic test.

Conditions

  • Stable Coronary Artery Disease
  • Acute Coronary Syndrome
  • Percutaneous Coronary Intervention

Interventions

GENETIC

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers

Patients found to carry the CYP2C19\*2 allele will receive prasugrel 10 mg daily for 1 week. Non-carriers will receive clopidogrel 75 mg daily.

Sponsors & Collaborators

  • Spartan Bioscience Inc.

    collaborator INDUSTRY

  • Ottawa Heart Institute Research Corporation

    lead OTHER

Principal Investigators

  • Derek Y.F. So, MD · Ottawa Heart Institute Research Corporation

  • Jason D. Roberts, MD · Ottawa Heart Institute Research Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01184300 on ClinicalTrials.gov